Oculis Holding AG (NASDAQ:OCS) is set to showcase its late-stage ophthalmology pipeline at the 44th Annual J.P. Morgan Healthcare Conference on January 14, following a pivotal start to the year.
The Swiss biopharma, led by CEO Riad Sherif, M.D., enters the investor circuit with newly granted FDA Breakthrough Therapy designation for its lead neuro-ophthalmology candidate, Privosegtor.
The Breakthrough status was bolstered by striking results from the ACUITY Phase 2 trial, where patients with acute optic neuritis—a condition often signaling the onset of multiple sclerosis—gained an average of 18 ETDRS letters at three months.
The gain significantly outperformed the placebo-plus-steroid group, marking a potential shift toward the first-ever neuroprotective therapy for a $7 billion U.S. market opportunity in optic neuropathies.
To solidify this path, Oculis recently initiated PIONEER-1, the first of three trials in its global registrational program.
The company is also making strides in its primary ophthalmology program, OCS-01, an eye drop designed to replace invasive injections for diabetic macular edema (DME).
Fully enrolled, the DIAMOND Phase 3 trials are on track for a topline readout in the second quarter of 2026, with an NDA submission slated for the end of the year.
With nearly $300 million in cash as of late 2025, Oculis is positioned to fund its dual-track strategy through these critical regulatory and clinical inflection points.